vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与COMSCORE, INC.（SCOR）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是COMSCORE, INC.的1.6倍（$152.6M vs $93.5M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 3.2%，领先31.3%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs -1.5%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $2.9M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 3.8%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
CPRX vs SCOR — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $93.5M |
| 净利润 | $52.7M | $3.0M |
| 毛利率 | 82.9% | 41.0% |
| 营业利润率 | 40.5% | 7.0% |
| 净利率 | 34.5% | 3.2% |
| 营收同比 | 7.6% | -1.5% |
| 净利润同比 | -5.8% | -3.7% |
| 每股收益（稀释后） | $0.40 | $9.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $93.5M | ||
| Q3 25 | $148.4M | $88.9M | ||
| Q2 25 | $146.6M | $89.4M | ||
| Q1 25 | $141.4M | $85.7M | ||
| Q4 24 | $141.8M | $94.9M | ||
| Q3 24 | $128.7M | $88.5M | ||
| Q2 24 | $122.7M | $85.8M | ||
| Q1 24 | $98.5M | $86.8M |
| Q4 25 | $52.7M | $3.0M | ||
| Q3 25 | $52.8M | $453.0K | ||
| Q2 25 | $52.1M | $-9.5M | ||
| Q1 25 | $56.7M | $-4.0M | ||
| Q4 24 | $55.9M | $3.1M | ||
| Q3 24 | $43.9M | $-60.6M | ||
| Q2 24 | $40.8M | $-1.7M | ||
| Q1 24 | $23.3M | $-1.1M |
| Q4 25 | 82.9% | 41.0% | ||
| Q3 25 | 84.7% | 40.6% | ||
| Q2 25 | 85.9% | 40.6% | ||
| Q1 25 | 87.3% | 39.6% | ||
| Q4 24 | 84.7% | 42.4% | ||
| Q3 24 | 85.0% | 41.2% | ||
| Q2 24 | 87.4% | 39.5% | ||
| Q1 24 | 87.3% | 42.3% |
| Q4 25 | 40.5% | 7.0% | ||
| Q3 25 | 44.7% | 1.9% | ||
| Q2 25 | 45.2% | -1.9% | ||
| Q1 25 | 44.8% | -2.4% | ||
| Q4 24 | 44.3% | 4.1% | ||
| Q3 24 | 39.6% | -67.4% | ||
| Q2 24 | 44.2% | -2.2% | ||
| Q1 24 | 27.5% | -2.2% |
| Q4 25 | 34.5% | 3.2% | ||
| Q3 25 | 35.6% | 0.5% | ||
| Q2 25 | 35.6% | -10.6% | ||
| Q1 25 | 40.1% | -4.7% | ||
| Q4 24 | 39.4% | 3.3% | ||
| Q3 24 | 34.1% | -68.5% | ||
| Q2 24 | 33.2% | -2.0% | ||
| Q1 24 | 23.6% | -1.2% |
| Q4 25 | $0.40 | $9.50 | ||
| Q3 25 | $0.42 | $-0.86 | ||
| Q2 25 | $0.41 | $-2.73 | ||
| Q1 25 | $0.45 | $-1.66 | ||
| Q4 24 | $0.44 | $-0.47 | ||
| Q3 24 | $0.35 | $-12.79 | ||
| Q2 24 | $0.33 | $-1.19 | ||
| Q1 24 | $0.19 | $-1.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $23.6M |
| 总债务越低越好 | — | $41.5M |
| 股东权益账面价值 | $954.3M | $111.4M |
| 总资产 | $1.1B | $407.7M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $23.6M | ||
| Q3 25 | $689.9M | $26.7M | ||
| Q2 25 | $652.8M | $26.0M | ||
| Q1 25 | $580.7M | $31.0M | ||
| Q4 24 | $517.6M | $29.9M | ||
| Q3 24 | $442.3M | $20.0M | ||
| Q2 24 | $375.7M | $14.7M | ||
| Q1 24 | $310.4M | $18.7M |
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $954.3M | $111.4M | ||
| Q3 25 | $920.2M | $-26.3M | ||
| Q2 25 | $856.0M | $-21.7M | ||
| Q1 25 | $794.3M | $-13.5M | ||
| Q4 24 | $727.6M | $-8.3M | ||
| Q3 24 | $660.9M | $-2.7M | ||
| Q2 24 | $608.7M | $45.8M | ||
| Q1 24 | $561.4M | $51.4M |
| Q4 25 | $1.1B | $407.7M | ||
| Q3 25 | $1.1B | $406.9M | ||
| Q2 25 | $971.9M | $415.9M | ||
| Q1 25 | $908.9M | $421.5M | ||
| Q4 24 | $851.4M | $430.2M | ||
| Q3 24 | $772.0M | $412.5M | ||
| Q2 24 | $706.4M | $474.1M | ||
| Q1 24 | $646.7M | $477.7M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $3.2M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $2.9M |
| 自由现金流率自由现金流/营收 | 29.4% | 3.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | 0.85× | 1.07× |
| 过去12个月自由现金流最近4个季度 | — | $21.8M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $3.2M | ||
| Q3 25 | $32.4M | $9.5M | ||
| Q2 25 | $71.3M | $932.0K | ||
| Q1 25 | $60.0M | $9.1M | ||
| Q4 24 | $70.9M | $-10.0M | ||
| Q3 24 | $72.9M | $12.5M | ||
| Q2 24 | $64.1M | $8.7M | ||
| Q1 24 | $31.9M | $6.9M |
| Q4 25 | $44.9M | $2.9M | ||
| Q3 25 | — | $9.4M | ||
| Q2 25 | $71.3M | $787.0K | ||
| Q1 25 | — | $8.7M | ||
| Q4 24 | $70.8M | $-10.3M | ||
| Q3 24 | $72.6M | $12.4M | ||
| Q2 24 | $64.1M | $8.5M | ||
| Q1 24 | $31.7M | $6.6M |
| Q4 25 | 29.4% | 3.1% | ||
| Q3 25 | — | 10.5% | ||
| Q2 25 | 48.6% | 0.9% | ||
| Q1 25 | — | 10.1% | ||
| Q4 24 | 49.9% | -10.8% | ||
| Q3 24 | 56.4% | 14.0% | ||
| Q2 24 | 52.3% | 10.0% | ||
| Q1 24 | 32.2% | 7.6% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | 0.1% | 0.2% | ||
| Q3 24 | 0.2% | 0.1% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.2% | 0.3% |
| Q4 25 | 0.85× | 1.07× | ||
| Q3 25 | 0.61× | 20.96× | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | -3.19× | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
